蛋白酶体抑制剂与免疫调节治疗相互作用加重多发性骨髓瘤治疗中的复发性心脏毒性
多发性骨髓瘤患者接受免疫调节药物和蛋白酶体抑制剂治疗时心血管并发症发生率增加。本文报告一例仅在联合暴露于蛋白酶体抑制剂与免疫调节药物为基础的方案时出现复发性心脏毒性的多发性骨髓瘤患者,并回顾相关文献,提出该人群心脏毒性预防的潜在算法。
要点
- 多发性骨髓瘤患者暴露于部分免疫调节药物和蛋白酶体抑制剂时心血管并发症发生率增加。
- 本文报告一例仅在联合暴露于蛋白酶体抑制剂与免疫调节药物为基础治疗时出现复发性心脏毒性的患者。
- 作者回顾相关文献并提出该人群心脏毒性预防的潜在算法。
核心结论
- 多发性骨髓瘤患者的心血管副作用可能因蛋白酶体抑制剂与免疫调节药物联合地塞米松而加重。
研究设计与样本
- 本文报告一例多发性骨髓瘤患者并回顾相关文献。
主要发现
- 该患者仅在暴露于蛋白酶体抑制剂与免疫调节药物联合方案时出现复发性心脏毒性。
临床怎么用
- 作者提出该人群心脏毒性预防的潜在算法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) have improved treatment options, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Despite their efficacy, increased rates of cardiovascular (CV) complications occur in patients exposed to some of these therapies. While previous research has focused on identifying the toxicities inherent to each specific agent, the CV side effects may be potentiated by the combination of PIs and IMiDs plus dexamethasone. We present a patient with MM with recurrent cardiotoxicity only when exposed to combination PI and IMiD-based therapy. We also review the literature in this context, and propose a potential algorithm for cardiotoxicity prevention in this population.
引用
- Fradley MG, Groarke JD, Laubach J, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2017. PMID: 29048105. doi:10.1111/bjh.14970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。